Versant Capital Management Inc Purchases 146 Shares of Illumina, Inc. (NASDAQ:ILMN)

Versant Capital Management Inc boosted its position in Illumina, Inc. (NASDAQ:ILMN) by 153.7% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 241 shares of the life sciences company’s stock after acquiring an additional 146 shares during the quarter. Versant Capital Management Inc’s holdings in Illumina were worth $32,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Empowered Funds LLC boosted its stake in Illumina by 1.7% during the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock valued at $516,000 after purchasing an additional 66 shares during the period. Caprock Group LLC lifted its holdings in shares of Illumina by 3.0% during the third quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock worth $376,000 after buying an additional 83 shares during the last quarter. Integrated Advisors Network LLC boosted its position in shares of Illumina by 2.0% in the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock valued at $585,000 after acquiring an additional 90 shares during the period. Moors & Cabot Inc. boosted its position in shares of Illumina by 1.7% in the third quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock valued at $759,000 after acquiring an additional 95 shares during the period. Finally, Carson Advisory Inc. grew its stake in shares of Illumina by 3.8% in the third quarter. Carson Advisory Inc. now owns 2,757 shares of the life sciences company’s stock worth $360,000 after acquiring an additional 102 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Up 0.3 %

ILMN stock opened at $139.08 on Wednesday. The business has a fifty day moving average price of $141.62 and a 200 day moving average price of $131.98. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. Illumina, Inc. has a fifty-two week low of $100.08 and a fifty-two week high of $156.66. The stock has a market capitalization of $22.06 billion, a price-to-earnings ratio of -13.96 and a beta of 1.11.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. During the same quarter last year, the company posted $0.33 EPS. The company’s quarterly revenue was down 3.5% compared to the same quarter last year. Analysts expect that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ILMN shares. JPMorgan Chase & Co. increased their price target on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Citigroup cut shares of Illumina from a “buy” rating to a “neutral” rating and reduced their target price for the company from $190.00 to $165.00 in a research note on Wednesday, December 11th. Barclays boosted their price target on Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Piper Sandler cut their price target on Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a report on Monday, November 11th. Finally, Leerink Partners lifted their price objective on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Eight analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $165.95.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.